<?xml version="1.0" encoding="UTF-8"?>
<p>Inactivated ASF vaccines were first attempted in 1960s, but studies have shown that inactivated ASFV as a vaccine is essentially an infeasible strategy [
 <xref rid="B43-vaccines-08-00531" ref-type="bibr">43</xref>]. In 2014, ASFV-specific antibodies were detected in piglets vaccinated with binary ethyleneimine (BEI)-inactivated ASFV Armenia08 strain in combination with the latest Polygen
 <sup>TM</sup> or Emulsigen
 <sup>Â®</sup> -D adjuvant, but the strain failed to provide protection and acute clinical symptoms were quickly observed [
 <xref rid="B44-vaccines-08-00531" ref-type="bibr">44</xref>]. Inactivated vaccines are antigenic but lacked the capability to stimulate the body to produce complete cellular immune responses, which may be part of the reasons why inactivated vaccines cannot provide immune protection [
 <xref rid="B45-vaccines-08-00531" ref-type="bibr">45</xref>].
</p>
